Share Email Print
cover

Proceedings Paper

Molecular beacon-based photodynamic therapy
Author(s): Juan Chen; Klara Stefflova; Soungkyoo Kim; Hui Li; Diane Marotta; Britton Chance; Jerry D. Glickson; Gang Zheng
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

A new concept for photodynamic therapy (PDT) has been developed based on incorporating a photosensitizer (PS) and a singlet oxygen (1O2) quenching/scavenging molecule (Q) onto a disease-targeting carrier, such that the PS becomes activatable by light only when targeting has occurred. This has the potential to give very high disease specificity in PDT treatment. The first model compound designed using this concept was synthesized containing a pyropheophorbide as the PS and a carotenoid as the 1O2 quencher. These were kept in close proximity by the self-folding of a caspase-3 specific peptide sequence. Upon caspase-3-induced cleavage, the 1O2 production increase has been validated by direct 1O2 luminescence and lifetime measurements, providing proof-of-concept of this 'PDT beacon.'

Paper Details

Date Published: 18 January 2005
PDF: 10 pages
Proc. SPIE 5630, Optics in Health Care and Biomedical Optics: Diagnostics and Treatment II, (18 January 2005); doi: 10.1117/12.573915
Show Author Affiliations
Juan Chen, Univ. of Pennsylvania (United States)
Klara Stefflova, Univ. of Pennsylvania (United States)
Soungkyoo Kim, Univ. of Pennsylvania (United States)
Hui Li, Univ. of Pennsylvania (United States)
Diane Marotta, Univ. of Pennsylvania (United States)
Britton Chance, Univ. of Pennsylvania (United States)
Jerry D. Glickson, Univ. of Pennsylvania (United States)
Gang Zheng, Univ. of Pennsylvania (United States)


Published in SPIE Proceedings Vol. 5630:
Optics in Health Care and Biomedical Optics: Diagnostics and Treatment II
Britton Chance; Mingzhe Chen; Arthur E. T. Chiou; Qingming Luo, Editor(s)

© SPIE. Terms of Use
Back to Top